VYUITY Drug Insight and Market Forecast - 2032

"VYUITY Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VYUITY for Presbyopia in the 7MM. A detailed picture of the VYUITY for Presbyopia in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the VYUITY for Presbyopia. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VYUITY market forecast, analysis for Presbyopia in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Presbyopia.

Drug Summary:

VUITY (AGN-190584), developed by Allergan (which was acquired by AbbVie), is a mitotic 1.25% pilocarpine hydrochloride ophthalmic solution for the treatment of presbyopia in adults. It is a cholinergic muscarinic receptor agonist formulated as an isotonic, colorless, sterile solution.

Its active ingredient, pilocarpine hydrochloride, activates muscarinic receptors on smooth muscles like the iris sphincter and the ciliary muscle. It contracts the sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light. It also contracts the ciliary muscle, thus shifting the eye to a more myopic state.

VUITY is a topical, once-daily drop delivered by a proprietary vehicle that uses PhAST technology for rapid adjustment to the physiologic pH of the tear film. It is the first FDA-approved eye drop to treat presbyopia, an eye condition that affects nearly half of the US adult population. The approval was based on results from two pivotal Phase III studies, GEMINI 1 and GEMINI 2, which demonstrated the drugs' effectiveness to improve near and intermediate vision without impacting distance vision using the eye's own ability to reduce the pupil size.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VYUITY description, mechanism of action, dosage and administration, research and development activities in Presbyopia.
• Elaborated details on VYUITY regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VYUITY research and development activity in Presbyopia in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VYUITY.
• The report contains forecasted sales of VYUITY for Presbyopia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Presbyopia.
• The report also features the SWOT analysis with analyst views for VYUITY in Presbyopia.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VYUITY Analytical Perspective by DelveInsight

In-depth VYUITY Market Assessment

This report provides a detailed market assessment of VYUITY in Presbyopia in the 7MM, i.e., United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

VYUITY Clinical Assessment

The report provides the clinical trials information of VYUITY in Presbyopia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Presbyopia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VYUITY dominance.
• Other emerging products for Presbyopia are expected to give tough market competition to VYUITY and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VYUITY in Presbyopia.
• Our in-depth analysis of the forecasted sales data of VYUITY from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VYUITY in Presbyopia.

Key Questions

• What is the product type, route of administration and mechanism of action of VYUITY?
• What is the clinical trial status of the study related to VYUITY in Presbyopia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VYUITY development?
• What are the key designations that have been granted to VYUITY for Presbyopia?
• What is the forecasted market scenario of VYUITY for Presbyopia?
• What are the forecasted sales of VYUITY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Presbyopia and how are they giving competition to VYUITY for Presbyopia?
• Which are the late-stage emerging therapies under development for the treatment of Presbyopia?